Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Department of Immunology and Hematology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
J Egypt Natl Canc Inst. 2022 Mar 28;34(1):13. doi: 10.1186/s43046-022-00110-x.
Despite antitumor properties, chemotherapy medication can create conditions in tumor cells that work in favor of the tumor. Doxorubicin, commonly prescribed chemotherapy agents, can increase the risk of migration and invasion of tumor cells through overexpression of the CXCR4 gene by affecting downstream signaling pathways. The regulatory role of CXCR7 on CXCR4 function has been demonstrated. Therefore, it is hypothesized that combining doxorubicin with another anticancer drug could be a promising approach.
In this research, we evaluated the anti-invasive property of pioglitazone along with antitumor effects of doxorubicin on MDA-MB-231 breast cancer cell lines.
There was no significant difference between two treatment groups in neither the expression nor changes in the expression of CXCR7 and CXCR4 genes (P < 0.05). Pioglitazone-doxorubicin combination reduced cell migration in tumor cells to a significantly higher extent compared to doxorubicin alone (P < 0.05).
Co-administration of pioglitazone and doxorubicin might reduce cell migration in breast cancer tumor cells, and that cell migration function is independent of some specific proteins.
尽管抗肿瘤药物具有抗肿瘤特性，但它也能在肿瘤细胞中创造有利于肿瘤的条件。阿霉素是一种常用的化疗药物，它可以通过影响下游信号通路，过度表达 CXCR4 基因，增加肿瘤细胞迁移和侵袭的风险。CXCR7 对 CXCR4 功能的调节作用已经得到证实。因此，人们假设将阿霉素与另一种抗癌药物联合使用可能是一种有前途的方法。
在这项研究中，我们评估了吡格列酮联合阿霉素对 MDA-MB-231 乳腺癌细胞系的抗肿瘤作用和抗侵袭特性。
两组治疗方法在 CXCR7 和 CXCR4 基因的表达或变化方面均无显著差异（P<0.05）。与单独使用阿霉素相比，吡格列酮-阿霉素联合用药显著降低了肿瘤细胞的迁移（P<0.05）。
联合使用吡格列酮和阿霉素可能会降低乳腺癌肿瘤细胞的迁移，而细胞迁移功能与某些特定蛋白无关。
